Online Lifestyle Intervention (iLIVE) for Prostate Cancer Survivors
This study, called iLIVE, is testing an online program for men with prostate cancer who have received androgen deprivation therapy (ADT). ADT can lead to weight gain, obesity, and frailty (weakness and decreased physical function). The iLIVE program includes online supervised group resistance training and an interactive website with diet and weight loss information. Researchers want to see if iLIVE can reduce obesity and improve frailty in these survivors. The study aims to enroll 250 participants and is currently unclear regarding its recruitment status. Success will be measured by changes in overweight/obesity, sarcopenia (muscle loss), and slowness over 3, 6, and 12 months.
- Study design
- This interventional study will randomize participants to either the iLIVE online program or usual care with educational information. It aims to enroll 250 participants.
- What's involved
- Participants will either engage in online resistance training and use a diet website, or receive educational materials. All participants will use a Fitbit and smart scale.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months after completing the intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kerri Winters-Stone, PhD · PRINCIPAL_INVESTIGATOR · OHSU Knight Cancer Institute
- Wendy Demark-Wahnefried, PhD, RD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in overweight/obesityAt baseline, 3 months, 6 months and 12 months
Measured from weight assessed on the Aria (registered trademark) scale at the time of the online assessment and self-reported height. Overweight is defined as body mass index \> 25 kg/m\^2 and a 5% loss will be viewed as a successful outcome.
- Change in sarcopeniaAt baseline and 6 months
Measured by 30 mg D3 creatine (D3Cr) capsule which they will ingest and then urinate on a test strip on the second void upon waking 3-6 days later. The enrichment of D3Cr will be measured from the test strip along with urine creatine and creatinine. Will use a cutoff of \< 10.75 kg/m\^2 (moderate sarcopenia).
- Change in slownessAt baseline, 3 months and 6 months
Measured by the fastest time of two 4m walks at a usual pace administered by study staff by remote teleconference. Will use a cut point for "slowness" in older men of speed \< 1.0 m/s - a clinically meaningful cutoff that predicts falls and loss of independence.
- Change in weaknessAt baseline, 3 months, and 6 months
Measured by the seconds required to rise from a chair five times, administered by study staff by remote teleconference. Chair stand time \> 12 seconds predicts a 2.4 increased risk of falls in older adults and we will apply this cutoff for "weakness."
- Change in inactivityAt baseline, 3 months, 6 months, and 12 months
Measured by physical activity-related energy expenditure, calculated from self-report on the 41-item Community Health Activities Model Program for Seniors (CHAMPS) physical activity questionnaire. We will use \< 383 kcals per week spent in moderate-vigorous intensity activity as our low activity cut point. Measured also by Fitbit.
- Change in fatigueAt baseline, 3 months, 6 months, and 12 months
Measured using the 4-item short form (SF)-36 Vitality Scale. Will use cut points of scores of \< 50.00 (normed) for prostate cancer survivors (PCS) aged 50-64 years or scores less than 40.00 (normed) for PCS aged 65+ years.